^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    threitolceramide 6 liposomal (PORT-2)

    i
    Other names: PORT-2, IMM60 liposomal, ThrCer6
    Associations

    News

    Trials
    Company:
    Portage
    Drug class:
    iNKT agonist
    Related drugs:
    Associations

    News

    Trials
    26d
    KEYNOTE-E69: IMM60 and Pembrolizumab in Melanoma and NSCLC (clinicaltrials.gov)
    P1/2, N=1, Terminated, iOx Therapeutics | Trial completion date: Dec 2026 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Apr 2024; Prioritization of other pipeline assets. No safety or efficacy issues were observed.
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • threitolceramide 6 liposomal (PORT-2)
    4ms
    KEYNOTE-E69: IMM60 and Pembrolizumab in Melanoma and NSCLC (clinicaltrials.gov)
    P1/2; Recruiting --> Active, not recruiting | N=100 --> 1
    Enrollment change • Enrollment closed • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • threitolceramide 6 liposomal (PORT-2)
    6ms
    KEYNOTE-E69: IMM60 and Pembrolizumab in Melanoma and NSCLC (clinicaltrials.gov)
    P1/2; Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • BRAF mutation • PD-L1 negative
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • threitolceramide 6 liposomal (PORT-2)
    over1year
    IMM60 and Pembrolizumab in Melanoma and NSCLC (clinicaltrials.gov)
    P1/2; N=100; Not yet recruiting; Sponsor:iOx Therapeutics
    New P1/2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • BRAF mutation • PD-L1 negative
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • threitolceramide 6 liposomal (PORT-2)